ECSP20082970A - Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso - Google Patents

Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso

Info

Publication number
ECSP20082970A
ECSP20082970A ECSENADI202082970A ECDI202082970A ECSP20082970A EC SP20082970 A ECSP20082970 A EC SP20082970A EC SENADI202082970 A ECSENADI202082970 A EC SENADI202082970A EC DI202082970 A ECDI202082970 A EC DI202082970A EC SP20082970 A ECSP20082970 A EC SP20082970A
Authority
EC
Ecuador
Prior art keywords
drug
methods
antibody conjugates
sez6
sez6 antibodies
Prior art date
Application number
ECSENADI202082970A
Other languages
English (en)
Inventor
Alexander Schammel
David Liu
Julia Gavrilyuk
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of ECSP20082970A publication Critical patent/ECSP20082970A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan nuevos anticuerpos anti-SEZ6 y conjugados de fármaco y anticuerpo, y los métodos para usar tales anticuerpos anti-SEZ6 y los conjugados de fármaco y anticuerpo para tratar el cáncer.
ECSENADI202082970A 2018-05-30 2020-12-23 Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso ECSP20082970A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862678061P 2018-05-30 2018-05-30

Publications (1)

Publication Number Publication Date
ECSP20082970A true ECSP20082970A (es) 2021-01-29

Family

ID=66998493

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202082970A ECSP20082970A (es) 2018-05-30 2020-12-23 Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso

Country Status (32)

Country Link
US (4) US20210196834A1 (es)
EP (2) EP3710485B8 (es)
JP (1) JP6936399B2 (es)
KR (1) KR20210018316A (es)
CN (1) CN112135843A (es)
AU (1) AU2019278870A1 (es)
BR (1) BR112020024223A2 (es)
CA (1) CA3097199A1 (es)
CL (1) CL2020003044A1 (es)
CO (1) CO2020016151A2 (es)
CR (1) CR20200623A (es)
CY (1) CY1124183T1 (es)
DK (1) DK3710485T3 (es)
EC (1) ECSP20082970A (es)
ES (1) ES2867148T3 (es)
HR (1) HRP20210631T1 (es)
HU (1) HUE053616T2 (es)
IL (1) IL278225A (es)
LT (1) LT3710485T (es)
MA (1) MA51453A (es)
MX (1) MX2020012788A (es)
NZ (1) NZ768778A (es)
PE (1) PE20211497A1 (es)
PH (1) PH12020551968A1 (es)
PL (1) PL3710485T3 (es)
PT (1) PT3710485T (es)
RS (1) RS61770B1 (es)
RU (1) RU2770474C1 (es)
SG (1) SG11202011576VA (es)
SI (1) SI3710485T1 (es)
SM (1) SMT202100368T1 (es)
WO (1) WO2019232241A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022240117A1 (ko) 2021-05-10 2022-11-17 강원대학교 산학협력단 항체 결합 재조합 융합 단백질 및 이를 이용한 항체-약물 접합체
KR102819556B1 (ko) 2021-05-10 2025-06-13 강원대학교산학협력단 항체 결합 재조합 융합 단백질 및 이를 이용한 항체-약물 접합체
US20240091374A1 (en) * 2022-08-26 2024-03-21 Abbvie Inc. Anti-sez6 antibody drug conjugates
WO2024230742A1 (zh) 2023-05-08 2024-11-14 上海翰森生物医药科技有限公司 一种抗体或其抗原结合片段、抗体-药物偶联物及其应用
WO2025167503A1 (en) * 2024-02-05 2025-08-14 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-sez6/b7h3 antibodies and uses thereof
CN119409821B (zh) * 2024-10-18 2025-07-29 北京大学第一医院(北京大学第一临床医学院) 一种抗sez6纳米抗体或抗原结合片段与应用
CN120365421B (zh) * 2025-04-24 2025-11-04 成都古格尔生物技术有限公司 一种特异性抗sez6靶点的全人源抗体及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5879936A (en) 1988-04-18 1999-03-09 Aluguisse Holding A.G. Recombinant DNA methods, vectors and host cells
SI2371392T1 (sl) * 2002-05-02 2015-10-30 Wyeth Holdings Llc Konjugati derivat-nosilec kaliheamicina
AR048098A1 (es) * 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
MX2007001221A (es) 2004-08-04 2007-03-23 Amgen Inc Anticuerpos para proteina dickkopf-1 (dkk-1).
CA2810016A1 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
CA2865415C (en) * 2012-02-24 2022-06-21 Stem Centrx, Inc. Anti sez6 antibodies and methods of use
WO2015003154A1 (en) 2013-07-03 2015-01-08 Histosonics, Inc. Articulating arm limiter for cavitational ultrasound therapy system
AU2014312215B2 (en) * 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
AU2014312310A1 (en) * 2013-08-28 2016-04-07 Abbvie Stemcentrx Llc Novel SEZ6 modulators and methods of use
MA41645A (fr) * 2015-03-04 2018-01-09 Abbvie Stemcentrx Llc Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
JP2018515457A (ja) * 2015-04-21 2018-06-14 アッヴィ・ステムセントルクス・エル・エル・シー カリケアマイシン構築物および使用方法
WO2017112803A1 (en) * 2015-12-22 2017-06-29 Abbvie Stemcentrx Llc Novel anti-mmp16 antibodies and methods of use
JP2019526529A (ja) * 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート

Also Published As

Publication number Publication date
US20210196834A1 (en) 2021-07-01
CR20200623A (es) 2021-07-01
WO2019232241A1 (en) 2019-12-05
IL278225A (en) 2020-11-30
CN112135843A (zh) 2020-12-25
JP2021508694A (ja) 2021-03-11
NZ768778A (en) 2022-07-01
BR112020024223A2 (pt) 2021-03-16
SMT202100368T1 (it) 2021-07-12
EP3858863A1 (en) 2021-08-04
EP3710485B1 (en) 2021-03-31
SG11202011576VA (en) 2020-12-30
ES2867148T3 (es) 2021-10-20
US20250213714A1 (en) 2025-07-03
SI3710485T1 (sl) 2021-08-31
EP3710485B8 (en) 2021-06-23
PH12020551968A1 (en) 2021-09-13
JP6936399B2 (ja) 2021-09-15
DK3710485T3 (da) 2021-05-10
AU2019278870A1 (en) 2020-10-29
CL2020003044A1 (es) 2021-04-16
RU2770474C1 (ru) 2022-04-18
MA51453A (fr) 2020-09-23
CO2020016151A2 (es) 2021-05-31
EP3710485A1 (en) 2020-09-23
KR20210018316A (ko) 2021-02-17
US20210338831A1 (en) 2021-11-04
HUE053616T2 (hu) 2021-07-28
RS61770B1 (sr) 2021-05-31
US11077203B2 (en) 2021-08-03
PE20211497A1 (es) 2021-08-11
PT3710485T (pt) 2021-05-04
LT3710485T (lt) 2021-05-10
MX2020012788A (es) 2021-02-15
CA3097199A1 (en) 2019-12-05
CY1124183T1 (el) 2022-05-27
HRP20210631T1 (hr) 2021-05-28
PL3710485T3 (pl) 2021-09-13
US20200316215A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
ECSP20082970A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CL2019000334A1 (es) Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357)
DOP2018000138A (es) Nuevos anticuerpos anti-claudina y sus métodos de uso
MX2020013169A (es) Conjugados de camptotecina.
ECSP18038868A (es) Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll
AR120147A1 (es) Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
CL2017003240A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
MX2019003780A (es) Uso de la combinación de anticuerpo anti-pd-1 e inhibidor de vegfr en la preparación de medicamentos para el tratamiento de cánceres.
PE20160870A1 (es) Anticuerpos anti-claudina novedosos y metodos de uso
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
MX2022006132A (es) Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
MX2020010110A (es) Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos.
MX2018013484A (es) Nuevos anticuerpos anti-tnfrsf21 y modos de uso.
CL2017002680A1 (es) Construcciones de calicheamicina y sus métodos de uso
AR108690A1 (es) Anticuerpos contra el miembro 21 de la superfamilia del receptor del factor de necrosis tumoral (anti-tnfrsf21) y métodos de uso de los mismos
EA202092941A1 (ru) Конъюгаты камптотецина
AR101757A1 (es) Anticuerpos anti-mfi2 y métodos de uso
AR110347A1 (es) Anticuerpos anti-kremen2 y métodos para su uso